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Abstract
MicroRNAs (miRNAs) have emerged as important post-transcriptional regulators of gene expression in many
developmental and cellular processes. Moreover, there is now ample evidence that perturbations in the levels of
individual or entire families of miRNAs are strongly associated with the pathogenesis of a wide range of human
diseases. Indeed, disease-associated miRNAs represent a new class of targets for the development of miRNA-based
therapeutic modalities, which may yield patient benefits unobtainable by other therapeutic approaches. The recent
explosion in miRNA research has accelerated the development of several computational and experimental
approaches for probing miRNA functions in cell culture and in vivo. In this review, we focus on the use of
antisense oligonucleotides (antimiRs) in miRNA inhibition for loss-of-function studies. We provide an overview of
the currently employed antisense chemistries and their utility in designing antimiR oligonucleotides. Furthermore,
we describe the most commonly used in vivo delivery strategies and discuss different approaches for assessment
of miRNA inhibition and potential off-target effects. Finally, we summarize recent progress in antimiR mediated
pharmacological inhibition of disease-associated miRNAs, which shows great promise in the development of novel
miRNA-based therapeutics.
Introduction
MicroRNAs (miRNAs) are an abundant class of small
(approximately 22 nt) endogenous non-coding RNAs
that direct post-transcriptional regulation of gene
expression. Metazoan miRNAs regulate a wide range of
biological processes, including developmental timing,
apoptosis, differentiation, cell proliferation and metabo-
lism [1-6]. Moreover, there is ample evidence that dysre-
gulation of individual or entire families of miRNAs is
associated with the pathogenesis of human diseases,
such as cancer, CNS disorders, viral infections, cardio-
vascular and metabolic diseases [7-12].
The first miRNA genes, lin-4 and let-7, were discov-
ered in C. elegans by Victor Ambros and Gary Ruvkun,
and shown to base-pair imperfectly to 3’ untranslated
regions (UTRs) of heterochronic genes, thereby control-
ling timing of larval development in the worm [13-15].
To date 18,226 miRNAs have been annotated in ani-
mals, plants and viruses, including 1,527 miRNAs
encoded in the human genome [16]. miRNAs are either
expressed from independent transcriptional units or
derive from introns of protein-coding genes or exons or
introns of long ncRNAs. Approximately 50% of the
mammalian miRNAs are located within introns of pro-
tein-coding genes [17,18]. The primary transcripts of
miRNA genes, termed pri-miRNAs, are usually several
kilobases long and possess a 5’ CAP and a poly(A) tail
[19,20]. Pri-miRNAs are processed in the nucleus to
approximately 70 nt hairpin-structures, known as pre-
miRNAs (Figure 1), by the nuclear Microprocessor com-
plex, consisting of DGCR8 and the RNase III enzyme
Drosha [21-23]. Pre-miRNAs are exported to the cyto-
plasm by Exportin-5 [24-27] and processed further by
Dicer, to approximately 22 nt double-stranded miRNA
duplexes (Figure 1) [28-32]. The miRNA duplexes are
loaded into an Argonaute protein in the miRNA-
induced silencing complex (miRISC) and rapidly
unwound. During this process the mature miRNA is
retained in the miRISC, whereas the complementary
strand, known as the miRNA star (miR*), is released
[33,34].
Most metazoan miRNAs guide the miRISC to par-
tially complementary sites located in the 3’ UTRs of
target mRNAs, and, thereby, promote their transla-
tional repression or deadenylation and degradation
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reproduction in any medium, provided the original work is properly cited.[34,35]. A key specificity determinant for miRNA tar-
get recognition is based on Watson-Crick pairing of
the so-called seed region (nucleotides 2 to 8) in the
mature miRNA to the seed match site in the target 3’
UTR, which nucleates the miRNA:target mRNA inter-
action [36]. The number of targets has been predicted
using genome-wide computational searches for con-
served seed match sites in mammalian 3’ UTRs, which
together with additional 3’-supplementary and 3’-com-
pensatory binding sites imply that miRNAs may
repress more than 60% of all mammalian protein-cod-
ing genes [36,37].
Identification and experimental validation of miRNA
targets is a key prerequisitef o ru n c o v e r i n gt h ew i d e -
spread biological roles of miRNAs and miRNA-mediated
gene regulatory networks. This has accelerated the
development of several computational, biochemical,
genetic and functional genomics approaches for miRNA
studies [36,38-44]. The most commonly used gain- and
loss-of-function strategies to probe miRNA functions in
vitro and in vivo are described in Table 1.
Currently, three approaches are used in miRNA loss-
of-function studies: genetic knockouts, miRNA sponges
and antisense oligonucleotides. Knockout mice lacking
key miRNA processing factors, such as Dicer, Drosha
and Ago2, are embryonic lethal, which demonstrates the
general importance of miRNAs in early embryonic
development [43]. Generation of miRNA gene knock-
outs has been extensively used to unravel the functions
of miRNAs in C. elegans and Drosophila,a n dh a sa l s o
been reported for many individual miRNAs in the
mouse [8,10,65-71]. Recently, a genome-wide miRNA
knockout resource covering 476 mouse miRNA genes
was described, and has now been made available from
ES cell repositories for distribution to the scientific com-
munity [72]. The use of miRNA sponges, which are
highly expressed transgenes harboring multiple miRNA
target sites to sequester miRNAs, represents another
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polymerase II into long primary miRNA transcripts, termed pri-miRNAs that are usually several kilobases long and possess a 5’ CAP and a poly(A)
tail. Pri-miRNAs are processed in the nucleus to ~70 nt pre-miRNAs by the nuclear Microprocessor complex, consisting of DGCR8 and the RNase
III enzyme Drosha. Pre-miRNAs are exported to the cytoplasm by Exportin-5 and processed further by Dicer, to ~22 nt double-stranded miRNA
duplexes that are loaded into an Argonaute protein in the miRISC and rapidly unwound. During this process the mature miRNA is retained in
the miRISC, whereas the complementary strand, known as the miRNA star (miR*) is released. Metazoan miRNAs guide the miRISC to partially
complementary sites in the 3’ UTRs of target mRNAs to promote their translational repression or deadenylation and degradation. Chemically
modified antimiR oligonucleotides sequester the mature miRNA in competition with cellular target mRNAs leading to functional inhibition of the
miRNA and derepression of the direct targets.
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studies [73]. This approach enables both transient and
long-term inhibition of entire miRNA seed families in
cultured cells and has also been applied to manipulate
miRNA activity in Drosophila and mice (reviewed by
Ebert and Sharp [45]). Interestingly, systemic adminis-
tration of a lentiviral sponge for miR-326 was shown to
reduce the number of IL-17 secreting Th-17 cells and
ameliorate experimental autoimmune encephalomyelitis
(EAE) in mice [47]. These findings highlight the poten-
tial of virally delivered miRNA sponges in the develop-
ment of miRNA-based gene therapies.
A widely employed approach in miRNA loss-of-func-
tion studies is to use chemically modified antisense oli-
gonucleotides, termed antimiRs, which sequester the
mature miRNA in competition with cellular target
mRNAs leading to functional inhibition of the miRNA
and derepression of the direct targets (Figure 1). Here,
we describe the current designs of chemically modified
antimiR oligonucleotides and provide an overview of
antimiR in vivo delivery strategies. In addition, we dis-
cuss the assessment of miRNA inhibition and off-target
effects, as well as the utility of antimiR compounds in
pharmacological inhibition of disease-implicated miR-
NAs for therapeutics.
Design of chemically modified antimiR
oligonucleotides
MiRNA inhibition by antimiRs requires optimization of
the oligonucleotides for increased binding affinity,
improved nuclease resistance and in vivo delivery. This
can be achieved using a variety of chemical modifica-
tions, including modifications of the sugar, the nucleo-
base or the internucleotide linkages (Figure 2A, B).
Sequence-specific inhibition of miRNA function was
first demonstrated in cultured HeLa cells using 2’-O-
methyl (2’-O-Me) modified RNA oligonucleotides com-
plementary to mature miRNAs [74,75]. The 2’-O-Me
modification as well as the 2’-O-methoxyethyl (2’-MOE)
and 2’-fluoro (2’-F) chemistries are modified at the 2’
position of the sugar moiety, whereas locked nucleic
acid (LNA) comprises a class of bicyclic RNA analogues
in which the furanose ring in the sugar-phosphate back-
bone is chemically locked in a RNA mimicking N-type
(C3’-endo) conformation by the introduction of a 2’-
O,4’-C methylene bridge (Figure 2A) [50,76-80]. All the
aforementioned modifications confer nuclease resistance
and increase the binding affinity of antimiR oligonucleo-
tides to their cognate miRNAs. Among these, LNA pos-
sesses the highest affinity towards complementary RNA
with an increase in duplex melting temperature (Tm)o f
+2 to 8°C per introduced LNA monomer against com-
plementary RNA compared to unmodified duplexes
[80-83]. Another important observation is that LNA
monomers are also able to twist the sugar conformation
of flanking DNA nucleotides from an S-type (C2’-endo)
towards an N-type sugar pucker in LNA-modified DNA
oligonucleotides [80,84]. Indeed, structural studies of
different LNA-RNA and LNA-DNA heteroduplexes
based on NMR spectroscopy and X-ray crystallography
have shown that LNA-modified DNA oligonucleotides
are RNA mimics, which fit seamlessly into an A-type
Watson-Crick duplex geometry [84,85] similar to that of
dsRNA duplexes.
Nuclease resistance is also improved by backbone
modification of the parent phosphodiester linkages into
phosphorothioate (PS) linkages in which a sulfur atom
replaces one of the non-bridging oxygen atoms in the
phosphate group (Figure 2A) or by using morpholino
oligomers, in which a six-membered morpholine ring
replaces the sugar moiety. Morpholinos are uncharged,
inherently resistant to degradation by nucleases and
Table 1 Strategies to manipulate microRNA activity for gain- and loss-of-function studies
Loss-of-function
Technology Characteristics In vitro In vivo References
Genetic knockout animals Constitutive or conditional Primary cells Systemic or organ-specific [43]
miRNA sponges Transient to long-term
inhibition
Transfection or viral
delivery
Lentivirus or AAV-mediated delivery [45-47]
antimiR oligonucleotides Transient (in vitro) to long-
lasting inhibition
Transfection or
unassisted uptake
Unconjugated or 3’-cholesterol modified, i.v.,
s.c. or i.p. delivery
[48-50]
Target protectors Transient Transfection Embryo injection (zebrafish) [51-54]
Gain-of-function
Technology Characteristics In vitro In vivo References
Transgenic animals Constitutive or conditional Primary cells Systemic or organ-specific [55,56]
Synthetic miRNA mimics Transient Transfection Intratumoral injection, ex vivo transfection of
cells, i.v. delivery
[57-62]
Vector-mediated miRNA
over-expression
Transient to long-term over-
expression
Transfection or viral
delivery
Lentivirus or AAV-mediated delivery,
intranasal delivery
[58-60,63,64]
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NAs [86]. Morpholino oligomers have been shown to be
sequence-specific, non-toxic and potent inhibitors of
both pri-miRNA and mature miRNA activity in zebra-
fish and Xenopus laevis [87-89].
Several studies have evaluated the potency of different
chemically modified antimiR oligonucleotides in miRNA
inhibition [76,77,90-93]. Two studies used luciferase
reporter assays to compare different antimiR designs in
targeting of miR-21 in HeLa cells. Davis et al. [76]
showed a loose correlation between binding affinity and
in vitro antimiR potency and found that among the fully
PS modified antimiRs investigated, those with the high-
est Tm,au n i f o r m2 ’Fa n daL N A / 2 ’-MOE mixmer anti-
miR, were the most potent miR-21 inhibitors. Similarly,
Lennox and Behlke [92] reported that incorporation of
high affinity modifications to antimiR oligonucleotides
improved their potency. In their study, LNA/2’-O-Me
mixmers with PS ends or with a complete PS backbone
showed highest potency, being approximately 10 times
more potent than a uniform 2’-O-Me modified antimiR.
Consistent with these observations, we found that inhi-
bition of miR-122 function in cultured Huh-7 cells by
different LNA/DNA mixmers was affinity dependent
and identified a LNA-modified antimiR with a high Tm
of 80°C, which mediated efficient de-repression of a
miR-122 luciferase reporter upon co-transfection of the
antimiR-122 into Huh-7 cells at 5 nM concentration
[90]. Moreover, this antimiR-122 was also the most
potent inhibitor of HCV RNA accumulation in Huh-7
cells harboring the HCV-N replicon, compared with a
2’-O-Me oligonucleotide and two LNA-antimiRs of
lower affinity [90]. Effective targeting of miR-122 by
LNA/2’-O-Me and 2’-F/MOE modified antimiRs (Figure
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Figure 2 Design of chemically modified antimiR oligonucleotides. (A) Structures of the most commonly used chemical modifications in
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studies to date, fully complementary antimiRs have been
used to target the mature miRNA. Notably, truncation
of a uniform 2’-MOE-modified antimiR-21 and a choles-
terol-conjugated antagomir-122, respectively, by three or
more nucleotides was shown to result in substantial or
complete loss of efficacy in cultured cells and in vivo
[76,95]. By comparison, we and others have reported on
efficient antagonism of several miRNAs, using high-affi-
nity 15 to 16 nucleotide LNA-modified DNA/PS oligo-
nucleotides targeting the 5’ region of the mature
miRNA (Figure 2B) [11,90,96-102]. Furthermore, we
have recently described a method that enables inhibition
of miRNA function using short seed-targeting LNA oli-
gonucleotides, designated as tiny LNAs [103]. This
approach exploits the high binding affinity of fully LNA-
modified 8-mer PS oligonucleotides complementary to
the miRNA seed region (Figure 2B, C), which enables
specific and concentration-dependent inhibition of
entire miRNA seed families in cultured cells with conco-
mitant de-repression of direct targets [103]. Our data
highlight the importance of targeting the miRNA seed
for inhibition, as 8-mer LNAs targeting other regions in
mature miRNA sequences had no or limited effect on
miRNA activity. The importance of the high binding
affinity of fully substituted 8-mer LNAs was further
demonstrated by the fact that an 8-mer 2’-O-Me-modi-
fied antimiR-21 oligonucleotide with a low Tm of 37°C
showed no inhibition of miR-21 activity in HeLa cells
[103].
In vivo delivery of antimiR oligonucleotides
Inhibition of miRNA function in vivo was first described
in C. elegans by Hutvágner et al. [74]. In this study, a
2’-O-Me oligonucleotide complementary to let-7 was
microinjected in C. elegans larvae and shown to pheno-
copy the let-7 loss-of-function mutation [74]. The utility
of 3’ cholesterol-conjugated, 2’-O-Me oligonucleotides
with terminal PS modifications, termed antagomirs (Fig-
ure 2B), in pharmacological inhibition of miRNAs in
mice, was described in 2005 by Krutzfeldt et al. [104].
Treatment of mice with three tail vein injections of 80
mg/kg antagomir-16 resulted in silencing of miR-16 in
the liver, kidney, lung, heart, skeletal muscle, colon, fat,
skin, ovaries, adrenal glands and bone marrow, whereas
no efficacy was observed in the brain [104]. Further-
more, systemic delivery of antagomir-122 by three intra-
venous (i.v.) injections of 80 mg/kg led to efficient
inhibition of the liver-expressed miR-122 with concomi-
tant de-repression of liver mRNAs with miR-122 seed
match sites and a 40% decrease in serum cholesterol
levels in the treated mice [104]. Subsequent studies
showed that systemically delivered antagomir-122 accu-
mulates in a cytoplasmic compartment of hepatocytes
distinct from P-bodies and inferred an antagomir-
mediated degradation mechanism independent of the
RNAi pathway [95]. Moreover, efficient inhibition of
miR-16 in the brain was achieved by direct delivery of
antagomir-16 in the mouse cortex [95].
PS backbone modifications greatly improve the phar-
macokinetic properties of antisense oligonucleotides,
thereby facilitating their delivery in vivo [105]. Indeed,
several studies have reported efficient and long-lasting
silencing of miRNAs in vivo using unconjugated 2’-F/
MOE-, 2’-MOE- and LNA-modified antimiRs harboring
a complete PS backbone (Figure 2B)
[11,77,90,96,97,102,106-108]. We have described potent
and specific miR-122 silencing in vivo using a high-affi-
nity 15 nucleotide LNA/DNA mixmer PS oligonucleo-
tide complementary to the 5’ end of miR-122 [90].
Administration of unconjugated, saline-formulated
LNA-antimiR-122 to mice either intraperitoneally (i.p.)
or i.v. resulted in efficient uptake of the compound in
the liver, which coincided with a dose-dependent
sequestration of mature miR-122 in a highly stable het-
eroduplex with LNA-antimiR, inferring a different mode
of action compared to the degradation mechanism
described for antagomirs [95,104] and 2’-MOE-modified
oligonucleotides [106]. Using single i.p. injections of the
LNA-antimiR at doses ranging from 1 to 200 mg/kg we
observed a dose-dependent lowering of serum choles-
terol in mice with a median effective dose of 10 mg/kg,
whereas treatment of high fat diet-fed mice with 5 mg/
kg LNA-antimiR twice weekly for six weeks led to sus-
tained lowering of serum cholesterol by 30% and de-
repression of predicted target mRNAs with canonical
miR-122 seed match sites [90]. Moreover, systemic
administration of PBS-formulated LNA-antimiR to Afri-
can green monkeys at doses ranging from 1 to 10 mg/
kg with three i.v. infusions over five days resulted in
accumulation of the LNA-antimiR compound in the
liver and concomitant, dose-dependent sequestration of
mature miR-122 in a shifted LNA-antimiR:miR-122 het-
eroduplex in Northern blots. This led to a dose-depen-
dent and long-lasting decrease of serum cholesterol in
the treated primates, which gradually returned to base-
line levels over a three-month period after treatment.
Importantly, the LNA-antimiR compound was well tol-
erated in both mice and primates as no acute or sub-
chronic toxicities in the treated animals were detected
[90].
In a recent study, we investigated whether the high
binding affinity of seed-targeting tiny 8-mer LNA-anti-
miRs could enable delivery and silencing of miRNAs in
vivo without additional conjugation or formulation che-
mistries when combined with a complete PS backbone
[103]. A systemically delivered 8-mer antimiR-122 (three
i . v .d o s e so f5o r2 0m g / k g )w a ss h o w nt os e q u e s t e r
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repression of predicted miR-122 target mRNAs with
canonical 3’ UTR seed match sites and dose-dependent
lowering of serum cholesterol, which is consistent with
previous reports in rodents and non-human primates
[90,103,104,106]. Furthermore, a systemically delivered
35S-labeled tiny antimiR-21 showed uptake in many tis-
sues in mice with high levels of the compound accumu-
lating in the kidney cortex, liver, lymph nodes, bone
marrow and spleen with terminal half-lives ranging from
4 to 25 days [103]. The terminal elimination half-life in
heart blood was 8 to 10 hours and urine and bile were
indicated as primary routes of elimination. The tiny
antimiR-21 also sequestered the target miRNA in the
liver, kidney and lung coinciding with up-regulation of
the miR-21 target BTG2 in the same tissues [103].
These findings imply that tiny LNAs could become a
useful tool for functional studies of animal miRNAs in
vivo, since unlike other chemically modified antimiRs, 8-
mer LNAs enable inhibition of co-expressed miRNA
family members that may have redundant biological
functions.
Assessment of miRNA inhibition
The effect of miRNA inhibition by antimiR oligonucleo-
tides can be assessed by a variety of approaches. Most
methods that directly measure changes in miRNA levels
are hybridization based assays and associated with sev-
eral possible caveats when antimiR mediated miRNA
inhibition is assessed. First, the antimiR chemistry
appears to dictate the fate of the targeted miRNA. High-
affinity oligonucleotides, such as LNA/DNA, LNA/2’-O-
Me and 2’-F/MOE modified antimiRs, respectively,
sequester the targeted miRNA in a heteroduplex
[77,90,96,102,103,107,109], whereas lower affinity oligo-
nucleotides, such as 2’-O-Me and 2’-MOE modified
antimiRs and cholesterol-conjugated 2’-O-Me antago-
mirs, promote miRNA degradation [77,104,106,109]. A
recent study in Drosophila reported that extensive com-
plementarity between Ago1-loaded miRNA and its tar-
get RNA can trigger tailing and 3’-to-5’ exonucleolytic
trimming of the miRNA causing a decrease in mature
miRNA abundance [110]. Notably, miRNA tailing and
trimming were also observed in HeLa cells transfected
with antagomirs fully complementary to miR-16 and
miR-21, respectively [110], which is consistent with
antagomir-mediated degradation of miRNAs descibed
previously in mice [104]. We and others have reported
on detection of stable antimiR:miR heteroduplexes as
slower-migrating bands on small RNA Northern blots
(Figure 3) [90,96,102,103,107,109,111]. However, this
can be technically challenging due to difficulties in the
recovery and detection of the heteroduplexes [109]. Sec-
ond, the presence of excess antimiR in the RNA sample
irrespective of the mechanism of action may interfere
with the detection step of the assay, for example, primer
annealing or extension in miRNA-specific real-time
qPCR. The observed miRNA reduction in the readouts
from such experiments could, therefore, be misleading
due to the antimiR masking effects in the assays. Finally,
antimiRs may be released from subcellular compart-
ments during tissue homogenization and RNA extrac-
tion, thereby facilitating hybridization between the
antimiR and the target miRNA during sample prepara-
tion. To help circumvent these pitfalls, especially for
small RNA Northern blot analysis, it has been suggested
to use stringent denaturing conditions during electro-
phoresis [104], to increase the hybridization temperature
[112], to use LNA detection probes [90,96,103,107,112]
or to include a competitor probe with an identical
sequence as the miRNA prior to electrophoresis to
release the miRNA from the miR:antimiR duplex
[77,109]. Taken together, due to the possible assay inter-
ference and technical difficulties in antimiR:miR hetero-
duplex recovery, evaluation of antimiR mediated
inhibition of miRNA function by direct methods should
be interpreted with some caution. Thus, we recommend
that direct measurements of the targeted miRNA should
always be accompanied with assessment of the func-
tional effects after miRNA antagonism, as outlined in
Figure 3.
Assays that measure a functional readout of miRNA
modulation by antimiRs are often employed to provide
substantial evidence for miRNA inhibition. These
approaches include miRNA reporter assays, assessment
of de-repression of direct targets by real-time qPCR,
Western blot analysis and genome-wide transcriptional
or proteomic analyses. A simple and very sensitive
approach involves construction of a miRNA reporter
that carries a single or multiple perfect match or bulged
miRNA binding sites in the 3’ UTR of a reporter gene,
such as luciferase or GFP. This method has been exten-
sively used in cultured cells to validate miRNA inhibi-
tion (Figure 3A) and also to compare the potency of
different chemically modified antimiR designs
[76,90,92,103,112]. Recently, a miR-21 luciferase reporter
was used in a mouse mammary tumor model to moni-
tor functional inhibition ofm i R - 2 1b yas e e d - t a r g e t i n g
antimiR-21 in vivo [103]. The antimiR specificity is typi-
cally assessed using control oligonucleotides, either by
introducing one or more mismatches in the antimiR
sequence or by using a scrambled sequence oligonucleo-
tide. The potencies of such control oligonucleotides are
expected to be markedly reduced, as shown in Figure
3B, in which the specificity of an 8-mer LNA-antimiR-
21 was assessed by introducing one or two adjacent mis-
matches at all possible nucleotide positions in an 8-mer
antimiR-21 sequence. Ideally, both control reporters
Stenvang et al. Silence 2012, 3:1
http://www.silencejournal.com/content/3/1/1
Page 6 of 17C
Bckdk
1
2
3
4
AldoA
F
o
l
d
 
d
e
r
e
p
r
e
s
s
i
o
n
(
q
R
T
-
P
C
R
)
LNA 
control
15-mer
8-mer
saline
LNA 
control
15-mer
8-mer
saline
1
2
3
4
s
a
l
i
n
e
8
-
m
e
r
L
N
A
 
c
o
n
t
r
o
l
m
i
R
-
1
2
2
U6
1
5
-
m
e
r
anti-
miR-122
m
i
R
-
1
2
2
:
8
-
m
e
r
 
m
i
R
-
1
2
2
:
1
5
-
m
e
r
 
duplex
mRNAs sorted from up- to down-regulated
s
a
l
i
n
e
antimiR-122
LNA
control
5
0
25
50
75
100
125
P
l
a
s
m
a
 
c
h
o
l
e
s
t
e
r
o
l
 
(
%
 
o
f
 
s
a
l
i
n
e
)
15-mer
5
8-mer
20 20 5 20 mg/kg
8-mer 15-mer
0.0
0.5
1.0
1.5
R
e
l
a
t
i
v
e
 
l
u
c
 
a
c
t
i
v
i
t
y
0   1    5   10    0    1   5   10    nM 
15-mer
DE
FG
miR-122 reporter
0 2000 4000 6000 8000 10000
Seed sites
ACACTCC
CACTCCA
m
o
c
k
a
n
t
i
m
i
R
-
2
1
L
N
A
 
c
o
n
t
r
o
l
m
i
R
-
2
1
U6 
m
i
R
-
2
1
:
8
-
m
e
r
d
u
p
l
e
x
- 1 nM  5 nM  mm scr 2´-O- Me
0.0
0.5
1.0
1.5
R
e
l
a
t
i
v
e
 
l
u
c
 
a
c
t
i
v
i
t
y
miR-21 reporter psiCHECK2
anti-
miR-21
LNA 
controls
5’- G  A   T   A   A  G  C   T  - 3’
C
 C
 C
  C
  C
   C  
C
G
A G
 T A
 A  T
  T  T
  G  A  
   C   G
TC
miR-21 reporter
psiCHECK2
seed 0.0 0.5 1.0 1.5
Relative luc activity
 3’- C  U  A   U  U  C  G   A  - 5’ 
B A
antimiR-122
anti-
miR-122
anti-
miR-122
antimiR-122
psi-
CHECK2
Seed sites
ACACTCC
CACTCCA
GGAGTGT
GAGTGTG
PM sites
8-mer
l
o
g
1
0
(
e
n
r
i
c
h
m
e
n
t
 
P
−
v
a
l
u
e
)
0 2000 4000 6000 8000 10000
−5
0
5
10
15
20
25
antimiR-122
Figure 3 Assessment of miRNA inhibition in cultured cells and in vivo. (A) Upper panel. Relative luciferase activity of the miR-21 reporter
containing a perfect match miR-21 target site co-transfected into HeLa cells with 1 or 5 nM tiny LNA-antimiR-21, or 5 nM 8-mer 2’-O-Me
antimiR-21, LNA mismatch (mm) or LNA scramble (scr) control oligonucleotides, respectively. Error bars represent s.e.m. Lower panel. Northern
blot analysis of miR-21 in HeLa cells transfected with 5 nM antimiR-21 or LNA scramble control. U6 is shown as control. (B) Relative luciferase
activity of the miR-21 reporter co-transfected into HeLa cells, with 5 nM tiny seed-targeting LNAs harbouring single or two adjacent mismatches
at all possible nucleotide positions in the antimiR-21 sequence (highlighted in red). (C) Relative luciferase activity of a miR-122 reporter
containing a perfect match miR-122 target site co-transfected into HeLa cells with pre-miR-122 and tiny 8-mer antimiR-122 or 15-mer antimiR-
122. Error bars represent s.e.m. (D) Northern blot analysis of liver RNAs from mice after treatment with three intravenous doses of 20 mg/kg 8-
mer antimiR-122, 15-mer antimiR-122 or LNA scramble control or with saline. The Northern blot was probed for miR-122 and U6. (E)
Quantification of the AldoA and Bckdk target mRNAs (same samples as in D, normalized to GAPDH; error bars, s.e.m.; n = 5). (F) Sylamer analyses
performed on microarray data from mouse liver RNAs after treatment with three intravenous doses of 20 mg/kg 8-mer antimiR-122 or 15-mer
antimiR-122. Shown are Sylamer enrichment landscape plots for 7 nt sequence words. The highlighted words in the plots correspond to
canonical miR-122 seed match sites and to perfect match binding sites for the 8-mer antimiR-122. (G) Total plasma cholesterol levels in mice
treated with three intravenous injections of 8-mer antimiR-122, 15-mer antimiR-122 or LNA scramble control or with saline (error bars, s.e.m.; n =
5). Adapted from Obad et al. [103].
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scrambled oligonucleotides should be included as speci-
ficity controls when assessing inhibition of miRNA func-
tion by miRNA reporter constructs.
The mechanism of miRNA-mediated mRNA repres-
sion involves both mRNA deadenylation and degrada-
tion and translational repression (Figure 1) [34,35].
Recent reports on simultaneous genome-wide measure-
ments of changes in mRNA and protein levels after per-
turbing miRNA levels showed good correlation between
mRNA and protein levels [39,40]. Thus, an alternative
or supplemental approach to employing miRNA repor-
t e ra s s a y si st ou s et h el e v e l so fd i r e c tt a r g e tm R N A s
and their encoded proteins as functional readouts of
miRNA silencing. Western blots are readily used to
demonstrate the effect of antimiR mediated inhibition
by assessing target de-repression at the protein level
[103,113-115]. However, the degree of miRNA target
de-repression is often modest and several high through-
put analyses following miRNA perturbation report
changes in mRNA levels of only 33 to 35% [116,117].
Moreover, proteomic studies that detect the effect of
miRNA modulation by measuring directly the protein
levels have reported that the average changes are less
than two-fold [39,40]. Hence, more sensitive methods,
such as qPCR or ELISA, might be better suited to esti-
mate antimiR effects on single direct targets, as shown
in Figure 3E for two direct miR-122 target mRNAs in
the mouse liver.
Given that a single miRNA has the potential to regu-
late hundreds of mRNA targets, high throughput meth-
ods that enable genome-wide transcriptional and
proteomic profiling offer the opportunity to get a broad
view of the effects of miRNA antagonism. Moreover,
effects of perturbing the miRNA activity can be detected
more robustly by assessing the combined effect on all
the predicted direct targets. Thus, in the case where sin-
gle target analysis is unable to find a significant effect,
the simultaneous analysis of a large group of target
mRNAs increases statistical power and can yield highly
significant findings. Expression microarrays have been
widely used in transcriptional profiling experiments and
have also been employed by several studies to assess
genome-wide transcriptional changes after modulation
of miRNA activity in cultured cells and in vivo
[37,39,40,90,103,107,118]. However, the recent develop-
ment in massively parallel sequencing technologies has
prompted many researchers to use RNA sequencing
(RNA-Seq) for genome-wide expression analyses. RNA-
Seq enables not only assessment of transcript levels with
unprecedented accuracy and a broad dynamic range, but
provides a detailed view of the entire transcriptome at a
level that can provide important information on, for
example, alternative splicing, RNA editing and other
post-transcriptional modifications without the require-
ment of prior knowledge needed for microarray probe
design [119]. RNA-Seq was recently used to compare
genome-wide transcriptional and proteomic changes
mediated by ectopic and endogenous miRNAs in human
and mouse cells [116,117], and to assess antagomir-
directed tailing and trimming of miRNAs in cultured
HeLa cells [110].
A widely used method of testing the significance after
modulation of miRNA activity on multiple targets is the
Kolmogorov-Smirnov test, which asks whether the dis-
tribution of antimiR-mediatedt r a n s c r i p t i o n a lc h a n g e s
observed for a set of target mRNAs is significantly dif-
ferent from a set of non-target mRNAs
[37,39,40,90,103,107,118]. While this type of analysis is
cut-off free, it requires ap r i o r iknowledge of miRNA
targets and is, thus, biased by the choice of target pre-
diction algorithm and by preselecting the miRNA targets
for analysis. An alternative, more unbiased approach to
analyzing the effect of miRNA perturbation on target
mRNAs is to use the Sylamer algorithm [120] that uses
expression changes measured after, for example, miRNA
silencing to rank genes and subsequently test the occur-
rence of all possible sequence motifs of a given length
relative to the sorted gene list. The landscape plots
resulting from this type of analysis (Figure 3F) show the
significance profiles of all sequence motifs of a given
length across the sorted gene list, as shown in Figure 3F
for two different LNA-modified antimiR oligonucleo-
tides targeting miR-122.
Assessment of off-target effects
The use of antimiR oligonucleotides as a tool in func-
tional miRNA studies or as a therapeutic modality car-
ries the inherent risk of affecting RNA species other
than the intended miRNA target. Thus, understanding
the effects of unwanted interactions between the anti-
miR oligonucleotide and endogenous nucleic acids is of
key importance and when appropriate, application of
this knowledge during the design of antimiR molecules
can help minimize off-target effects. The fact that longer
oligonucleotides have fewer perfectly matched comple-
mentary sites in the transcriptome than shorter is some-
times used to state that longer oligonucleotides are
more specific. However, this only holds true if the hybri-
dization stringency can be controlled. When antimiRs
are used in vivo, their interactions with RNA molecules
are bound to take place at a physiologically relevant
temperature and at reduced stringency. Thus, interac-
tions are likely to occur through imperfect base pairing
similar to, for example, non-specific priming observed in
PCR at low annealing temperatures. The incorporation
of chemical modifications, such as LNAs, into antimiRs,
has been shown to improve mismatch discrimination
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son-Crick base pairing rules makes it difficult to accu-
rately predict interaction sites for fully complementary
antimiRs.
Due to their small size, 8-mer seed-targeting antimiRs
have many predicted perfectly complementary sites in the
transcriptome. Hence, by using Watson-Crick base pairing
rules we are able to identify a substantial number of
mRNAs that can be considered as candidates for off-tar-
gets. However, this does not necessarily imply that such
sites are indeed occupied in the cell, nor is it given that
such interactions if they occur have functional conse-
quences by affecting the levels of the bound mRNAs or
their encoded proteins. To address these questions, we
have recently reported an empirical approach in which
transcriptional and proteomic profiling was applied to
measure the effects of tiny 8-mer LNAs in cell culture and
in vivo [103]. We first used the Sylamer algorithm [120] to
ask which sequence motifs were associated with differen-
tially expressed genes following tiny antimiR treatment.
While the direct effect of tiny LNA mediated miRNA
silencing was readily detected in all our experiments (Fig-
ure 3F and [103]) by significant overrepresentation of
miRNA seed match sites in the up-regulated mRNAs, no
enrichment of sequence motifs in mRNAs with tiny LNA
complementary sites was detected. This implies that pre-
dicted off-targets are randomly distributed across the
sorted gene lists, and that as a group, the predicted off-tar-
get mRNAs are not affected by the antimiR. Next, we used
proteomic data to measure the effect of tiny LNAs on pre-
dicted off-targets to test whether potential binding of tiny
LNAs to mRNAs could affect their translation. Our find-
ings showed that the distribution of expression changes
following tiny LNA mediated miRNA silencing differed
significantly when miRNA targets were compared to non-
targets, reflecting de-repression of direct targets. Contrary
to the effect observed on the miRNA targets, the levels of
proteins derived from mRNAs with tiny LNA complemen-
tary sites were not affected, implying that tiny LNAs do
not have a general effect on predicted off-target interac-
tion partners [103].
Another potential antimiR mediated off-target effect
was recently reported by Khan et al. [122], who showed
that transfection of miRNA mimetics or siRNAs into
cells leads to effects on endogenous miRNA targets.
These findings are consistent with a model in which the
exogenous si/miRNA competes with the endogenous
miRNA for miRISC and the consequent loss of available
miRISC leads to abrogation of endogenous miRNA
mediated regulation. Similar saturation-based effects
could be detected when analyzing data sets from anti-
miR cell culture experiments, which implied that treat-
ment with antimiRs leads to global effects on targets of
other endogenous miRNAs. This is consistent with the
notion that an antimiR oligonucleotide sequesters its
cognate miRNA in the miRISC complex, thereby ren-
dering it unavailable to other endogenous miRNAs.
However, further experiments are needed to pinpoint
the exact molecular mechanisms leading to the observed
effects and to fully understand the ramifications these
findings may have on endogenous miRNA function.
Therapeutic targeting of disease-associated
miRNAs
Manipulation of miRNA activity in vivo is of high inter-
est due to the aberrant expression and implication of
miRNAs in the pathogenesis of human diseases. The use
of antimiR oligonucleotides to target disease-associated
miRNAs is the most widely used approach to probe
their functions in vivo and shows great promise in the
development of novel miRNA-based therapeutics.
Indeed, an increasing number of studies have reported
successful therapeutic miRNA silencing in a variety of
animal disease models using antimiR oligonucleotides
(Table 2). This section highlights selected studies, in
which either 3’ cholesterol-conjugated antagomirs or
unconjugated, chemically modified antimiRs harboring a
complete PS backbone have been used to pharmacologi-
cally inhibit disease-associated miRNAs in vivo.
In an orthotopic xenograft model of metastatic breast
cancer, 4T1 cells were implanted into the mammary fat
pad of mice and miR-10b was targeted by antagomir-
10b to investigate the effects of the primary tumors and
t h e i rm e t a s t a t i cc a p a c i t y[ 1 2 3 ] .T h i si sav e r ya g g r e s s i v e
metastasis model and, therefore, antagomir treatment
was initiated already at day 2 after implantation to inter-
fere with early stages of metastasis. The antagomir com-
pound was administered i.v. twice weekly for three
weeks (50 mg/kg) and mice were analyzed at day 28.
Treatment did not reduce primary mammary tumor
growth of 4T1 cells, whereas a striking suppression in
the formation of lung metastases was observed (86%
reduction of pulmonary metastases). The inhibition of
miR-10b was validated by qRT-PCR and de-repression
of the direct miR-10b target Hoxd10. Specificity was
demonstrated by unaltered levels of miR-9 and miR-21
that are reported to be up-regulated in breast tumors
and unchanged miR-10a, which differs by only 1 nt
compared to the mature miR-10b sequence. In addition,
a miR-10b sponge approach phenocopied the antagomir
data, whereas no effect of miR-10b inhibition on lung
metastases from disseminated cells (tail vein injected
4T1 cells) was observed, suggesting that miR-10b is not
involved in late stage metastasis. The tolerability and
toxicity of the antagomir treatment was assessed by sev-
eral parameters, including behavior, body, lung and
heart weight, respectively, white blood cell and lympho-
cyte count, histopathological investigations of steatosis,
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most noticeable changes were the lowering of white
blood cells and lymphocytes for miR-10b antagomir and
as a suggested antagomir class effect; increased liver and
spleen size, and elevated serum levels of bilirubin, ALT
and AST [123].
Recently, miR-103 and miR-107 were shown to
directly regulate insulin sensitivity in vivo [128]. This
miRNA family was up-regulated in the liver of diet-
induced obese and ob/ob mice, which led to decreased
insulin sensitivity and enhanced hepatic glucose produc-
tion. Cholesterol-conjugated antagomir-103 was applied
to investigate the function of miR-103/107 in diabetes
and administered via the tail vein on two consecutive
days (15 mg/kg/dose). Targeting of miR-103/107 was
demonstrated by Northern blot analysis, qRT-PCR and
de-repression of the direct target Caveolin-1, whereas
specificity was shown using mismatched and scrambled
antagomirs. Silencing of miR-103/107 lowered plasma
glucose levels in obese but not in wild-type mice, and
improved glucose homeostasis and insulin sensitivity.
Furthermore, over-expression or antagomir mediated
silencing of miR-103/107 in diet-induced obese mice
lacking Caveolin-1 demonstrated a central role of
Caveolin-1 in mediating the miR-103/107 effects on glu-
cose tolerance and insulin sensitivity [128].
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease, in which a combination of genetic pre-
disposition and possible environmental factors triggers
an immune response directed against ubiquitous, mostly
Table 2 Therapeutic targeting of selected disease-associated miRNAs in vivo using antimiR oligonucleotides
miRNA Model antimiR chemistry Administration route Phenotype Reference
miR-
122
Chow-fed mice Cholesterol-conjugated
2’-O-Me antagomir
i.v. Lowering of serum cholesterol [104]
miR-
122
DIO mice 2’-MOE i.p. Lowering of serum cholesterol [106]
miR-
122
Chow-fed mice LNA i.v. Lowering of serum cholesterol [96]
miR-
122
DIO mice, African green monkeys LNA i.p., i.v. Lowering of serum cholesterol [90]
miR-
122
HCV-infected chimpanzees LNA i.v. Suppression of viremia [107]
miR-
10b
Mouse mammary tumor model Cholesterol-conjugated
2’-O-Me antagomir
i.v. Suppression of lung metastases [123]
miR-
132
Orthotopic mouse model of
human breast carcinoma
2’-O-Me Vessel-targeted
nanoparticle delivery i.
v.
Reduction of angiogenesis and tumor
burden
[124]
miR-
199b
Mouse model of heart failure Cholesterol-conjugated
2’-O-Me antagomir
i.p. Inhibition and reversal of cardiac
hypertrophy and fibrosis
[125]
miR-
328
Mouse model of atrial fibrillation Cholesterol-conjugated
2’-O-Me antagomir
i.v. Normalization of atrial fibrillation [126]
miR-21 Mouse model of lupus LNA i.v., i.p. Amelioration of autoimmune
splenomegaly
[115]
miR-17-
5p
Mouse xenograft model of
neuroblastoma
Cholesterol-conjugated
2’-O-Me antagomir
Intratumoral injection Inhibition of tumor growth [127]
miR-
103/
107
DIO and ob/ob mice Cholesterol-conjugated
2’-O-Me antagomir
i.v. Improved glucose homeostasis and
insulin sensitivity
[128]
miR-
138
NOD/SCID mice with
hydroxyapatixe implants
LNA ex vivo Enhanced bone formation [101]
miR-33 Ldlr
-/- mice 2’-F/MOE s.c. Increased serum HDL-C levels,
regression of atherosclerosis
[108]
miR-33 DIO mice LNA i.v. Increased serum HDL-C levels [11]
miR-33 Chow-fed mice n.d. i.v. Increased serum HDL-C levels [129]
miR-
380-5p
Orthotopic mouse model of
neuroblastoma
LNA, 2’-F/MOE i.p. Decreased tumor growth [130]
miR-
182
Mouse model of arthritis LNA ex vivo Amelioration of arthritis [54]
miR-
29c
db/db mice 2’-O-Me i.p. Reduced albuminuria and kidney
mesangial matrix accumulation
[131]
miR-
208a
Hypertensive rats LNA i.v. Improved cardiac function and survival
during heart failure
[102]
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cells and abnormal antibody-independent B and T cell
functions imply that B and T cells are important in the
pathogenesis of SLE (reviewed in [132,133]). The B6.
Sle123 mouse strain bears three lupus susceptibility loci
and develops an autoimmune syndrome that strongly
resembles human lupus disease, characterized by auto-
antibody production, lymphosplenomegaly and glomeru-
lonephritis. In a recent study, miR-21 was found to be
up-regulated in B and T cells of B6.Sle123 mice [115],
consistent with findings in another genetic mouse
model of lupus as well as in human lupus CD4
+ Tc e l l s
and B cells [134,135]. Silencing of miR-21 by i.p. deliv-
ered, unconjugated 8-mer seed-targeting antimiR-21
reversed splenomegaly, one of the cardinal manifesta-
tions of autoimmunity in B6.Sle123 mice and de-
repressed PDCD4 expression in vivo.I na d d i t i o n ,a n t i -
miR-21 treatment altered CD4
+/CD8
+ T cell ratios
towards those of the non-autoimmune control mice and
reduced Fas receptor-expressing B cells, suggesting that
miR-21 plays a critical role in regulating autoimmune
responses in lupus. Furthermore, these findings imply
that tiny seed-targeting LNAs can be used to inhibit
miRNAs in peripheral lymphocytes in vivo and that
pharmacological inhibition of miR-21 by an 8-mer anti-
miR-21 can alter the course of a systemic autoimmune
disease in lupus mice [115].
The miR-208a/b family and miR-499, designated as
MyomiRs, are located in the introns of three myosin
genes, Myh6, Myh7, and Myh7b, respectively, and play
critical roles in the control of pathological cardiac
hypertrophy, heart failure and myocardial infarction in
humans and mouse models of heart disease [10,136].
Genetic deletion of miR-208 in mice showed no pheno-
type at baseline, whereas in response to cardiac stress,
miR-208 knockout mice showed virtually no cardiomyo-
cyte hypertrophy or fibrosis [137,138]. In a recent study,
Montgomery et al. [102] investigated the cardioprotec-
tive effect of miR-208a loss-of-function in hypertensive
rats. Therapeutic silencing of miR-208a by subcuta-
neously (s.c.) delivered LNA-modified antimiR-208a led
to potent and sustained silencing of miR-208a in the rat
heart. Notably, the antimiR treatment prevented patho-
logical myosin switching and cardiac remodeling during
hypertension-induced heart failure in Dahl hypertensive
rats, and resulted in improved cardiac function, overall
health and survival. These data highlight the potential of
antimiR-based approaches to pharmacologically inhibit
cardiac miRNAs and strongly imply miR-208 as a thera-
peutic target for treatment of heart disease [102].
Perturbations in cholesterol homeostasis and lipid
metabolism are associated with several life-threatening
diseases, such as atherosclerosis, type II diabetes and
metabolic syndrome. In 2010, a number of independent
studies reported that miR-33a, which is embedded
within an intron of the sterol regulatory element-bind-
ing protein-2 (SREBP2) gene, targets the ATP-binding
cassette transporter A1 (ABCA1), an important regula-
tor of high-density lipoprotein (HDL) synthesis and
reverse cholesterol transport, for post-transcriptional
repression [11,12,129,139,140]. Interestingly, another
member of the miR-33 family, miR-33b, is found within
an intron of the SREBP-1c gene in human and primates,
whereas mice only have one miR-33 isoform corre-
sponding to miR-33a [11]. The mature sequences of
miR-33a and miR-33b differ by only two nucleotides
and share the same seed region, implying that the two
miR-33 family members have overlapping targets, and,
thus, redundant biological functions, including regula-
tion of cholesterol efflux in cells. Three in vivo studies
have used antimiR oligonucleotides to probe the func-
tions of miR-33 in cholesterol homeostasis in the
mouse. Marquart et al. [129] delivered antimiRs intrave-
nously (5 mg/kg/dose on three consecutive days) and
showed increased ABCA1 expression and HDL-choles-
terol levels in serum 12 days after administration,
whereas Najafi-Shoushtari et al. [11] injected a LNA-
modified antimiR-33 i.v. at a dose of 20 mg/kg for three
consecutive days, which resulted in efficient inhibition
of miR-33 and concomitant increase of HDL-C by 25%
in the mouse serum. More recently, a third in vivo
study targeting miR-33 was reported, in which low-den-
sity lipoprotein (LDL) receptor knockout mice with
established atherosclerotic plaques were treated with s.c.
delivered 2’F/MOE antimiR for four weeks (two s.c.
injections of 10 mg/kg the first week followed by weekly
injections of 10 mg/kg) [108]. Treatment of Ldlr
-/- mice
with antimiR-33 led to elevated circulating HDL-C levels
and enhanced reverse cholesterol transport to the
plasma, liver and feces. Moreover, several markers of
atherosclerotic plaque stability were increased, which
was consistent with plaque regression and lesion remo-
delling in antimiR-33 treated mice. Importantly, this
study showed that antimiR-33 oligonucleotides are able
to penetrate the atherosclerotic lesion to reach plaque
macrophages, in which they can enhance ABCA1
expression and cholesterol removal [108]. Together,
these studies demonstrate that pharmacological inhibi-
tion of miR-33 in vivo by antimiR-33 oligonucleotides
raises circulating HDL-C levels, enhances reverse choles-
terol transport and regresses atherosclerosis, implying
that therapeutic silencing of miR-33 could be a useful
strategy for the treatment of cardiovascular disease.
Therapeutic targeting of microRNA-122 for
treatment of hepatitis C virus infection
Hepatitis C virus (HCV) infection is a leading cause of
liver disease worldwide with over 180 million infected
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ing liver failure and hepatocellular carcinoma (HCC).
The current standard therapy, which combines pegy-
lated interferon-a with ribavirin provides sustained viro-
logic response rates in only about 50% of patients and is
also associated with many side effects [141]. New tar-
geted HCV therapies, including viral polymerase and
protease inhibitors have yielded encouraging results, but
the emergence of viral escape mutations during such
therapies requires a combination with other HCV drugs
to tackle viral resistance [142]. By comparison, therapeu-
tic approaches that target essential host functions for
HCV may provide a high barrier to resistance and, thus,
could provide an alternative strategy for the develop-
ment of new HCV therapeutics. The liver-expressed
miR-122 binds to two closely spaced miR-122 target
sites in the 5’ non-coding region (NCR) of the HCV
genome, resulting in up-regulation of viral RNA levels
[143]. This unusual interaction was first described by
Peter Sarnow in 2005 [143], and was subsequently con-
firmed by several reports [144-146], implying that miR-
122 is an essential host factor for HCV RNA accumula-
tion in infected liver cells. Notably, inhibition of miR-
122 by antimiR oligonucleotides leads to rapid loss of
HCV RNA in cultured liver cells, which makes miR-122
an attractive therapeutic target for antiviral intervention
[143,146]. In a recent study, Machlin et al. [147] investi-
gated the contributions of the two miR-122 molecules
by assessing the effects of miR-122 point mutations on
HCV viral RNA abundance. The data from stepwise
mutational analyses suggest a model for an oligomeric
miR-122-HCV complex in which one miR-122 molecule
binds to the 5’ terminus of the HCV RNA with 3’ over-
hanging nucleotides masking the 5’ terminal sequences
of the HCV genome. These findings suggest that miR-
122 protects the 5’ terminal viral sequences from
nucleolytic degradation or from inducing innate
immune responses to the RNA terminus [147].
Besides its role in modulating cholesterol homeostasis
and promoting HCV RNA abundance, miR-122 has also
been suggested to be important for maintaining liver
cell identity and reported to be down-regulated in HCC
[148-150]. Loss of miR-122 expression in HCC was
shown to be associated with poor prognosis, acquisition
of an invasive phenotype and with intrahepatic metasta-
sis [150-152]. The tumor-suppressive effects of miR-122
have been linked to several direct miR-122 targets impli-
cated in HCC tumorigenesis, such as cyclin G1, RHOA
and the metalloprotease ADAM17. Interestingly, other
studies have reported that miR-122 expression is either
maintained or increased in HCV-associated HCC
[150,153]. Moreover, Varnholt et al. [153] observed
strong up-regulation of miR-122 in an extended sample
set of HCV-induced dysplastic nodules and HCCs,
which implies that the role of miR-122 in HCV-derived
HCCs is different compared to that in HCCs of non-
HCV etiologies. While further studies are needed to
establish the potential risks associated with long-term
therapeutic silencing of miR-122, it is important to note
that short-term inhibition of miR-122 in rodents and
non-human primates was shown to be reversible [90,96],
and furthermore, that the duration of treatment of
HCV-infected patients with an antimiR-122 is expected
to be limited.
Several studies have reported on pharmacological inhi-
bition of miR-122 in mice using antimiR oligonucleo-
tides [77,90,96,100,104,106]. We have previously shown
that potent miR-122 antagonism can be achieved in
rodents and non-human primates using a high-affinity
15-mer LNA-modified antimiR-122. In this study, sys-
temic delivery of unconjugated, saline-formulated anti-
miR-122 resulted in efficient sequestration of miR-122
leading to a dose-dependent and long-lasting decrease
of serum cholesterol levels in mice and African green
monkeys without any evidence for acute or subchronic
toxicities in the study animals [90]. Moreover, this anti-
miR oligonucleotide was highly potent in inhibiting
HCV RNA accumulation in Huh-7 cells harboring the
HCV-N replicon NNeo/C-5B [90]. More recently, we
assessed the potential of miR-122 antagonism as a new
anti-HCV therapy in chimpanzees with chronic HCV
infection [107]. In this study, four chimpanzees infected
with HCV genotype 1 were treated with i.v. injections of
the 15 nt LNA-antimiR-122 on a weekly basis for 12
weeks, followed by a treatment-free period of about 12
weeks after dosing. Treatment of the HCV-infected
chimpanzees led to long-lasting suppression of HCV vir-
emia with no evidence for viral resistance or side effects
in the treated animals. Furthermore, transcriptional pro-
filing and histopathology of liver biopsies demonstrated
de-repression of target mRNAs with canonical miR-122
seed sites, down-regulation of interferon-regulated genes
a n di m p r o v e m e n to fH C V - i n d u c e dl i v e rp a t h o l o g y
[107]. The long-lasting suppression of HCV viremia
without viral rebound implies that the antimiR-122
approach has a high barrier to viral resistance. Further-
more, the fact that both miR-122 seed sites are con-
served in all HCV genotypes suggests that the antiviral
effect of antimiR-122 will be genotype-independent,
which was recently confirmed [154].
Indeed, this antimiR-122 compound, termed miravir-
sen, is the first miRNA-targeted drug to enter human
clinical trials. Data from phase 1 single (up to 12 mg/
kg) and multiple ascending dose (up to five doses of 5
mg/kg) safety studies in 77 healthy volunteers showed
that miravirsen is well tolerated, has an attractive phar-
macokinetic profile and clear dose-dependent pharma-
c o l o g y .I m p o r t a n t l y ,n od o s el i m i t i n gt o x i c i t i e sw e r e
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Pharma A/S advanced miravirsen into a phase 2a trial
to assess the safety, tolerability, pharmacokinetics and
antiviral activity of miravi r s e ni nt r e a t m e n t - n a ï v e
patients with chronic HCV genotype 1 infection
[155,156]. In this multiple ascending dose study patients
were enrolled sequentially to one of three cohorts (nine
active and three placebo per cohort) and miravirsen was
administered at doses of 3, 5 or 7 mg/kg as a total of
five weekly subcutaneous injections over 29 days. Treat-
ment with miravirsen provided robust, dose-dependent
anti-viral activity with a mean reduction of two to three
logs from baseline in HCV RNA (log10 IU/mL) that was
maintained for more than four weeks after the last dose
of miravirsen. Notably, four out of nine patients treated
at the highest dose (7 mg/kg) became HCV RNA unde-
tectable during the study [155,156]. No serious adverse
events were observed and only mild and infrequent
adverse events, such as headache, coryza and diarrhea
were reported. Furthermore, there were no clinically sig-
nificant changes in safety tests, vital signs or electrocar-
diograms [155,156]. As expected, pharmacological
inhibition of miR-122 in HCV patients resulted in
decreased levels of serum cholesterol, apoA and apoB.
Taken together, these data indicate that miravirsen
given as a four-week monotherapy to HCV patients pro-
vides long-lasting suppression of viremia, has a high bar-
rier to viral resistance and is well tolerated in patients
with chronic HCV infection.
Conclusions
The challenge of unravelling the myriad roles of hun-
dreds of miRNAs in many developmental and cellular
processes as well as in human disease pathogenesis calls
for continuous development of robust computational
and experimental approaches for studying miRNA func-
tions in cell culture and in vivo. Inhibition of miRNA
function by chemically modified antimiR oligonucleo-
tides has become an important and widely used
approach in miRNA loss-of-function studies and enables
inhibition of both single miRNAs and entire miRNA
seed families. Despite recent advances in the design and
use of antimiRs, experiments that seek to inhibit
miRNA function are associated with several possible pit-
falls when antimiR mediated miRNA inhibition is
assessed. Furthermore, the use of antimiR oligonucleo-
t i d e sa st o o l si nm i R N Al o s s - o f - f u n c t i o ns t u d i e so ra s
therapeutic modalities carries the inherent risk of affect-
ing RNA species other than the intended miRNA target.
Hence, adequate assessment of the functional effects
after miRNA inhibition and the physiological repercus-
sions of long-term miRNA antagonism in vivo,a sw e l l
as understanding the potential off-target effects resulting
from unwanted interactions between the antimiR oligo-
nucleotide and endogenous nucleic acids, are of key
importance for antimiR-based miRNA loss-of-function
studies and for the development of miRNA therapeutics.
Efficient in vivo delivery of antimiR oligonucleotides is
another critical factor for their successful use in vivo
and for the development of miRNA-based therapeutic
modalities. Many peripheral tissues can be effectively
targeted by systemically delivered chemically modified
antimiR oligonucleotides, which show good pharmacoki-
netic properties and tissue uptake along with high stabi-
lity in blood and tissues in vivo. A number of alternative
strategies for delivery of antisense oligonucleotides and
siRNAs are being pursued and these could also be
applied to antimiRs. For example, ligands for specific
cell surface receptors capable of being internalized can
be conjugated to oligonucleotides, thereby facilitating
both cellular uptake and cell type-specific delivery.
Nevertheless, recent findings that unconjugated, saline-
formulated antimiR oligonucleotides can be used in
miRNA silencing in vivo suggest that antimiRs are use-
ful tools for validating disease-associated miRNA targets
in animal disease models. Furthermore, the high potency
and metabolic stability of chemically modified antimiRs,
and the lack of acute and subchronic toxicities in
rodents and non-human primates highlights the poten-
tial of antimiRs in the development of novel therapeutic
modalities based on disease-associated miRNAs. Indeed,
recent data from the first phase 2 study in patients with
chronic HCV genotype 1 infection treated with the
LNA-modified antimiR-122 drug miravirsen showed
that this compound was well tolerated and provided
long-lasting suppression of viremia in HCV-infected
patients.
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